

AF/6A 1652

Docket No.: PF-0148-2 DIV
Response Under 37 C.F.R. 1.116 - Expedited Procedure
Examining Group 1652

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope
addressed to: Commissioner for Patents, Washington, D.C. 20231
on August 31, 2000
By: *[Signature]*
Printed: Nancy L. Glynn

Corres. and Mail
BOX AF

RECEIVED

SEP 07 2000

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hawkins et al.

Title: HUMAN PYROPHOSPHATASE

Serial No.: 09/415,540

Filing Date: 8-Oct-99

Examiner: Slobodyansky, E.

Group Art Unit: 1652

Box AF
Commissioner for Patents
Washington, D.C. 20231

AMENDMENT TRANSMITTAL FEE SHEET

Sir:

Transmitted herewith are the following for the above-identified application:

1. Return Receipt Postcard; and
2. Response to Final Office Action (4 pp., in duplicate).

The fee has been calculated as shown below.

Claims	Claims After Amendment		Claims Previously Paid For	=	Present Extra	Other Than Small Entity Rate Fee	Additional Fee(s)
Total Claims	6	-	20	=	0	\$18	\$0
Indep. Claims	2	-	3	=	0	\$78	\$0
First Presentation of Multiple Dependent Claim						+\$260	\$0

TOTAL \$ 0

☒ No additional fee is required.
☐ Please charge Deposit Account No. 09-0108 the amount of \$

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Deposit Account No. 09-0108. A duplicate copy of this sheet is enclosed.


Respectfully submitted,

INCYTE GENOMICS, INC.

Date: 8/31/00

[Signature]
Peng Ben Wang, J.D.
Reg. No. 41,420
Direct Dial Telephone: (650) 621-7574

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 849-8886



Docket No.: PF-0148-2 DIV

Response Under 37 C.F.R. 1.116 - Expedited Procedure

Examining Group 1652

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231

on August 31, 2000

By: Nancy L. Glynn

Printed: Nancy L. Glynn

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hawkins et al.

Title: HUMAN PYROPHOSPHATASE

Serial No.: 09/415,540

Filing Date: 8-Oct-99

Examiner: Slobodyansky, E.

Group/Art Unit: 1652

Box AF

Commissioner for Patents

Washington, D.C. 20231

RESPONSE TO OFFICE ACTION

Sir:

In response to the Office Action dated May 31, 2000 (Final Office Action, Paper Number 12), Applicants request reconsideration of the above-referenced patent application in view of the following amendments and remarks.

IN THE CLAIMS

Please amend claim 19 as indicated below. For the Examiner's convenience, the non-amended pending claims are also listed below.

18. (Reiterated) The method of claim 20, wherein before hybridization, the target polynucleotide is amplified by the polymerase chain reaction.

19. (Twice amended) An isolated polynucleotide selected from the group consisting of:

a) a polynucleotide sequence of SEQ ID NO:2,